Compare FULC & LEGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FULC | LEGH |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.1M | 480.0M |
| IPO Year | 2019 | 2018 |
| Metric | FULC | LEGH |
|---|---|---|
| Price | $14.60 | $19.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $15.88 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.2M | 130.3K |
| Earning Date | 10-29-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.95 |
| Revenue | N/A | ★ $180,497,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.07 |
| P/E Ratio | ★ N/A | $10.22 |
| Revenue Growth | ★ 2752.05 | 10.25 |
| 52 Week Low | $2.32 | $18.84 |
| 52 Week High | $15.74 | $29.45 |
| Indicator | FULC | LEGH |
|---|---|---|
| Relative Strength Index (RSI) | 72.49 | 42.32 |
| Support Level | $8.63 | $19.35 |
| Resistance Level | $15.74 | $20.38 |
| Average True Range (ATR) | 1.23 | 0.71 |
| MACD | 0.26 | 0.19 |
| Stochastic Oscillator | 82.56 | 51.04 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.